Search Results
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
Jun 07, 2026, 20:08 ET OriCell's GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
monthsMechanism and broader potentialGPC3 (Glypican-3) is overexpressed in more than 70% of hepatocellular carcinomas, as well as in gastric cancer, lung squamous cell carcinoma, and ovarian clear cell carcinoma — making it a highly specific and compelling target for cancer therapy. Ori-C101 is engineered
More news about: Oricell Therapeutics Holdings Limited
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] Contacts:Ariel
More news about: Antengene Corporation Limited
Jun 05, 2026, 16:14 ET Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1
sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., June 5, 2026 /PRNewswire/ -- AlphaDetect,
More news about: Alpha-1 Foundation
Jun 05, 2026, 14:07 ET Brayton Purcell LLP Highlights KQED Reporting on Federal Bill Affecting Artificial Stone Silicosis Claims
of whom were unaware of the dangers associated with cutting and polishing artificial stone until after becoming ill. The cost of treatment—including lung transplants for those who qualify—has largely been borne by state taxpayers, rather than through workers' compensation systems.Brayton
More news about: Brayton Purcell LLP
Jun 05, 2026, 12:30 ET Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference
June 5, 2026 /PRNewswire/ -- Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today presented new clinical findings demonstrating vapendavir, an investigational oral rhinovirus capsid inhibitor,
More news about: Altesa Biosciences Inc.
Jun 05, 2026, 10:00 ET Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring
More news about: Vcare PharmaTech
Jun 04, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Jun 04, 2026, 09:17 ET Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further,
More news about: Optellum
Jun 04, 2026, 08:39 ET Florida Cancer Specialists & Research Institute Real-World Evidence Abstract Highlights Progress and Gaps in Biomarker Testing for Lung Cancer
MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) Consortium Protocol 2, a prospective real-world study examining patterns in biomarker testing, treatment decision-making, and the barriers and workflows that shape care for patients with lung cancer in community settings.
More news about: Florida Cancer Specialists & Research Institute
Jun 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.Internationale Agentur
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.International Agency
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023; 389 (22): 2063 – 2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147: 237 – 243.International
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.International
More news about: Amgen
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
International real-world study of DLL3 expression in patients with small cell lung cancer (Międzynarodowe badanie rzeczywistej praktyki klinicznej dotyczące ekspresji DLL3 u pacjentów z drobnokomórkowym rakiem płuca). Lung Cancer. 2020;147:237-243.International Agency for Research
More news about: Amgen
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.International Agency
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063-2075.Rojo F, Corassa M, Mavroudis D, et al. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer. 2020;147:237-243.International
More news about: Amgen
Jun 03, 2026, 08:00 ET Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Durable, Mutation-Agnostic Anti-Tumor Activity in Non-Small Cell Lung Cancer ModelsNew data demonstrated ATNM-400's potential as a mutation-agnostic antibody radioconjugate therapy for NSCLC:Across a panel of four lung cancer cell lines spanning EGFR- and KRAS-driver mutations,
More news about: Actinium Pharmaceuticals, Inc.
Jun 03, 2026, 08:00 ET Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
The Danaher company expands its collaboration with AstraZeneca and Daiichi Sankyo to develop an end-to-end system for TROP2 NMR in non-small cell lung cancer NEWCASTLE, United Kingdom, June 3, 2026 /PRNewswire/ --
More news about: Leica Biosystems
Jun 03, 2026, 07:25 ET Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
patients who have run out of ARPI choices. The same resistance-targeting biology underlies the compelling activity we have reported in non-small cell lung cancer and breast cancer, positioning ATNM-400 as a potential pan-tumor backbone for large, resistance-driven patient populations, alone or in combination.
More news about: Actinium Pharmaceuticals, Inc.
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
Jun 02, 2026, 20:00 ET Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
divided into three stages: dose escalation, dose expansion, and indication expansion, enrolling a total of 192 patients, including those with small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), neuroendocrine carcinoma
More news about: Kelun-Biotech
Jun 02, 2026, 11:32 ET MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
years, the company has executed customized collections across more than 50 disease indications, including the major solid tumors (breast, colorectal, lung, prostate, hepatocellular carcinoma, pancreatic, ovarian, melanoma, gastric, head and neck, renal cell, bladder, endometrial, and sarcoma), hematologic
More news about: MT Group
Jun 02, 2026, 09:45 ET Piedmont Atlanta Hospital Reaches Milestone for Use of Extracorporeal Membrane Oxygenation
ECMO is similar to heart-lung bypass that a patient might be placed on during surgery, but it can be used for longer recoveries from severe cardiac or respiratory conditions, such
More news about: Piedmont Healthcare